Catalyst Wire Dossier Catalyst Wire Dossier

Refametinib

refametinib
Drug timelines are a Plus or Pro feature.

5 regulatory and trial events tracked for Refametinib, covering 2014-01-08 to 2021-04-08. Get the full timeline:

Most recent: Clinical Trial Update: Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) [Phase 2]

See pricing